Combined iridium 192 interstitial and external beam radiation therapy for the treatment of prostatic cancer.
Twenty-four patients with clinically palpable prostatic adenocarcinoma (stage B or C) were treated with a combination of interstitial radiation therapy and external beam radiation therapy following pelvic lymphadenectomy for accurate staging. Early results indicate a complete clinical response rate at 12 months of 77%, with a 4% complication rate (persisting rectal ulceration).
D001918:Brachytherapy; D006801:Humans; D007495:Iridium / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*
D011868:Radioisotopes; D007495:Iridium